Abstract P2-09-02: BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations
Year: 2013
Type: conference-abstract
Source: Cancer Research
Authors: LA Mina, RK Ramanathan, ZA Wainberg, LA Byers, R Chugh, JC Sachdev, D Matei, C Zhang, JW Henshaw, A Dorr, SB Kaye, JS de Bono
Institutions: Translational Genomics Research Institute, Royal Marsden NHS Foundation Trust, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, University of Michigan, Indiana University Indianapolis, Indiana University – Purdue University Indianapolis, BioMarin (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2045777794